It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In this study, 5-amino-nicotinic acid derivatives (1–13) have been designed and synthesized to evaluate their inhibitory potential against α-amylase and α-glucosidase enzymes. The synthesized compounds (1–13) exhibited promising α-amylase and α-glucosidase activities. IC50 values for α-amylase activity ranged between 12.17 ± 0.14 to 37.33 ± 0.02 µg/mL ± SEM while for α-glucosidase activity the IC50 values were ranged between 12.01 ± 0.09 to 38.01 ± 0.12 µg/mL ± SEM. In particular, compounds 2 and 4–8 demonstrated significant inhibitory activities against α-amylase and α-glucosidase and the inhibitory potential of these compounds was comparable to the standard acarbose (10.98 ± 0.03 and 10.79 ± 0.17 µg/mL ± SEM, respectively). In addition, the impact of substituent on the inhibitory potential of these compounds was assessed to establish structure activity relationships. Studies in molecular simulations were conducted to better comprehend the binding properties of the compounds. All the synthesized compounds were extensively characterized with modern spectroscopic methods including 1H-NMR, 13C–NMR, FTIR, HR-MS and elemental analysis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Imam Abdulrahman Bin Faisal University, Department of Nano-Medicine Research, Institute for Research and Medical Consultations (IRMC), Dammam, Saudi Arabia (GRID:grid.411975.f) (ISNI:0000 0004 0607 035X)
2 Imam Abdulrahman Bin Faisal University, Department of Clinical Pharmacy, Institute for Research and Medical Consultations (IRMC), Dammam, Saudi Arabia (GRID:grid.411975.f) (ISNI:0000 0004 0607 035X)
3 Imam Abdulrahman Bin Faisal University, Department of Nano-Medicine Research, Institute for Research and Medical Consultations (IRMC), Dammam, Saudi Arabia (GRID:grid.411975.f) (ISNI:0000 0004 0607 035X); Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia (GRID:grid.411975.f) (ISNI:0000 0004 0607 035X)
4 King Fahd University of Petroleum & Minerals, Chemistry Department, Dhahran, Saudi Arabia (GRID:grid.412135.0) (ISNI:0000 0001 1091 0356)
5 Monash University, School of Chemical Engineering, Selangor Darul Ehsan, Malaysia (GRID:grid.440425.3)
6 Zhejiang Gongshang University, School of Business Administration, College of International Education, Hangzhou, China (GRID:grid.413072.3) (ISNI:0000 0001 2229 7034)
7 Qassim University, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Buraidah, Saudi Arabia (GRID:grid.412602.3) (ISNI:0000 0000 9421 8094)